2024-03-29T07:36:16Zhttp://digital.csic.es/dspace-oai/requestoai:digital.csic.es:10261/98312020-07-03T12:00:08Zcom_10261_5063com_10261_5col_10261_5066
Antibodies to citrullinated human fibrinogen synthetic peptides in diagnosing rheumatoid arthritis
Pérez Rodríguez, María L.
Gómara Elena, María José
Ercilla, Guadalupe
Sanmartí, Raimon
Haro Villar, Isabel
RA diagnosis
Citrullinated peptides
Fibrinogen peptides
Rheumatoid arthritis
12 pages, 9 figures.-- PMID: 17585853 [PubMed].-- Printed version published on Jul 26, 2007.-- Supplementary information (figs. S1-S7, tables S1-S2, 25 pages) available at: http://pubs.acs.org/doi/suppl/10.1021/jm0701932/suppl_file/jm0701932si20070529_011932.pdf
Since aggressive therapy given early in the rheumatoid arthritis (RA) disease course has the greatest therapeutic potential, early diagnostic tests with both high specificity and sensitivity are desirable. Rheumatoid sera were found to contain antibodies against citrullinated peptides, which are considered to be highly specific markers of RA. In the present work several analogues of the α- and β-chains of fibrin peptides containing different degrees of citrullination have been synthesized and analyzed by ELISA using 111 sera from RA
patients. In addition, we have also investigated the synergistic effects of different presentation formats of the synthetic constructs. We have designed chimeric and cyclic peptides that bear different peptide sequences
within the same molecule. Our results indicate that the synthesis of peptides bearing fibrinogen and filaggrin domains could be a robust method for the design of useful diagnostic strategies in RA.
2009-01-23T11:44:30Z
2009-01-23T11:44:30Z
2007-06-23
artículo
Journal of Medicinal Chemistry 50(15): 3573-3584 (2007)
1520-4804
http://hdl.handle.net/10261/9831
10.1021/jm0701932
eng
http://dx.doi.org/10.1021/jm0701932
closedAccess
American Chemical Society